Korean prostate cancer drug safety under watch in major 6-Year study
NCT ID NCT06334120
Summary
This study is monitoring the safety of darolutamide, an already approved prostate cancer medication, in 600 Korean patients. Researchers will track side effects and see how well the drug works over time by reviewing patients' medical records during their regular doctor visits. The study will last about 6 years, with each participant followed for 1 year as part of their usual cancer care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE SENSITIVE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Multiple locations
RECRUITINGMultiple Locations, South Korea
Conditions
Explore the condition pages connected to this study.